Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 8.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,767,901 shares of the medical equipment provider's stock after acquiring an additional 140,531 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.89% of Zimmer Biomet worth $186,743,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of ZBH. CKW Financial Group raised its stake in Zimmer Biomet by 11.7% during the 4th quarter. CKW Financial Group now owns 955 shares of the medical equipment provider's stock valued at $101,000 after purchasing an additional 100 shares during the period. Dorsey & Whitney Trust CO LLC increased its stake in shares of Zimmer Biomet by 2.3% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock worth $485,000 after acquiring an additional 102 shares during the last quarter. M&T Bank Corp increased its stake in shares of Zimmer Biomet by 0.4% in the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock worth $2,834,000 after acquiring an additional 108 shares during the last quarter. MGO One Seven LLC increased its stake in shares of Zimmer Biomet by 5.1% in the fourth quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider's stock worth $238,000 after acquiring an additional 110 shares during the last quarter. Finally, Dakota Wealth Management increased its stake in shares of Zimmer Biomet by 1.3% in the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider's stock worth $1,016,000 after acquiring an additional 122 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ZBH. The Goldman Sachs Group dropped their price target on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. Truist Financial set a $101.00 target price on shares of Zimmer Biomet in a research report on Tuesday, May 6th. Barclays lowered their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research report on Monday, February 10th. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Finally, Raymond James lowered their target price on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Zimmer Biomet has a consensus rating of "Hold" and a consensus price target of $111.53.

Zimmer Biomet Stock Down 1.2%

NYSE ZBH opened at $91.65 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The firm has a 50-day simple moving average of $102.24 and a 200 day simple moving average of $105.48. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.92 and a twelve month high of $119.06. The stock has a market cap of $18.13 billion, a PE ratio of 20.60, a PEG ratio of 1.95 and a beta of 0.78.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The company's revenue for the quarter was up 1.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.94 earnings per share. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.05%. The ex-dividend date was Monday, March 31st. Zimmer Biomet's dividend payout ratio is 21.24%.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This trade represents a 14.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.39% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.